

Clinical Policy: Risperidone Long-Acting Injection (Perseris, Risperdal Consta)

Reference Number: ERX.SPA.179

Effective Date: 12.01.17

Last Review Date: 08.21

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Risperidone (Perseris[™], Risperdal Consta[®]) is an atypical antipsychotic.

FDA Approved Indication(s)

Risperdal Consta is indicated:

- For the treatment of schizophrenia
- For the maintenance treatment of bipolar I disorder as monotherapy or as adjunctive therapy to lithium or valproate

Perseris is indicated for the treatment of schizophrenia in adults.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions[™] that Perseris and Risperdal Consta are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Schizophrenia or Bipolar Disorder (must meet all):

1. Diagnosis of schizophrenia or bipolar disorder;
2. Prescribed by or in consultation with a psychiatrist;
3. Age ≥ 18 years;
4. Member meets one of the following (a or b):
 - a. History of non-adherence to oral antipsychotic therapy (*see Appendix D for examples*) and has established tolerability with oral risperidone;
 - b. Therapy was initiated in an inpatient setting during a recent (within 60 days) hospital admission;
5. Request meets one of the following (a or b):
 - a. For Perseris requests, dose does not exceed 120 mg every four weeks;
 - b. For Risperdal Consta requests, dose does not exceed 50 mg every two weeks.

Approval duration:

Commercial – Length of Benefit

Medicaid – 6 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Schizophrenia or Bipolar Disorder (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports one of the following (a or b):
 - a. Member is currently receiving the requested medication for a covered indication, and has received this medication for at least 30 days;
 - b. Therapy was initiated in an inpatient setting, for a covered indication, during a recent (within 60 days) hospital admission;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):
 - a. For Perseris requests, new dose does not exceed 120 mg every four weeks;
 - b. For Risperdal Consta requests, new dose does not exceed 50 mg every two weeks.

Approval duration:

Commercial – Length of Benefit

Medicaid – 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents;
- B.** Dementia-related psychosis.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
risperidone (Risperdal®)	Schizophrenia Adults: initially, 2 mg/day PO (as a single dose) or 1 mg PO BID; adjust as tolerated to the recommended target dose of 4 to 8 mg/day Effective dose range: 4 to 16 mg/day Bipolar Disorder Adults: initially, 2-3 mg PO QD Effective dose range: 1 to 6 mg/day	Schizophrenia: 16 mg/day Bipolar disorder: 6 mg/day

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to risperidone or paliperidone
- Boxed warning(s): increased mortality in elderly patients with dementia-related psychosis

Appendix D: Examples of Oral Antipsychotics – Generic (Brand)

Typical/First Generation Antipsychotics [†]	Atypical/Second Generation Antipsychotics
<ul style="list-style-type: none"> • Chlorpromazine (Thorazine[®]) • Fluphenazine (Prolixin[®]) • Haloperidol (Haldol[®]) • Loxapine (Loxitane[®]) • Perphenazine (Trilafon[®]) • Pimozide (Orap[®]) • Thioridazine (Mellaril[®]) • Thiothixene (Navane[®]) • Trifluoperazine (Stelazine[®]) 	<ul style="list-style-type: none"> • Aripiprazole (Abilify[®])* • Asenapine maleate (Saphris[®]) • Brexpiprazole (Rexulti[®]) • Cariprazine (Vraylar[®]) • Clozapine (Clozaril[®]) • Iloperidone (Fanapt[®]) • Lumateperone (Caplyta[®]) • Lurasidone (Latuda[®]) • Olanzapine (Zyprexa[®])* • Olanzapine/Fluoxetine (Symbyax[®]) • Paliperidone (Invega[®])* • Quetiapine (Seroquel[®]) • Risperidone (Risperdal[®])* • Ziprasidone (Geodon[®])

[†]Most typical/first generation antipsychotics are available only as generics in the U.S.

*Long-acting injectable formulation available

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Risperidone (Risperdal Consta)	Bipolar disorder, Schizophrenia	The recommended dose is 25 mg IM every 2 weeks. Some patients not responding to 25 mg may benefit from a higher dose of 37.5 mg or 50 mg.	50 mg every 2 weeks
Risperidone (Perseris)	Schizophrenia	90 mg or 120 mg SC once monthly	120 mg every 4 weeks

VI. Product Availability

Drug Name	Availability
Risperidone (Risperdal Consta)	Vial kits: 12.5 mg, 25 mg, 37.5 mg, and 50 mg
Risperidone (Perseris)	Extended-release injectable suspension: 90 mg, 120 mg

VII. References

1. Risperdal Consta Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2021. Available at <http://www.janssencns.com/risperdal>. Accessed March 22, 2021.
2. Perseris Prescribing Information. North Chesterfield, VA: Indivior, Inc.; December 2019. Available at: www.perseris.com. Accessed March 22, 2021.
3. Kim B, Lee SH, Yang YK, et al. Review Article: Long-acting injectable antipsychotics for first-episode schizophrenia: The pros and cons. Schizophr Res Treatment. August 14, 2012; 2012: 560836. doi:10.1155/2012/560836
4. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: <http://www.clinicalpharmacology-ip.com/>. Accessed March 22, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q17 Annual Review Policy split from ERX.SPMN.192 Long-acting injectable antipsychotics. Converted to new template. Added age restriction as safety and effectiveness have not been established in patients < 18 years.	10.02.17	11.17

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Removed “therapeutic plan includes an initial 3 weeks of concomitantly administered oral antipsychotic therapy with Risperdal Consta” since specialist is involved in care. Added max dose. Increased all approval durations to length of benefit. Bipolar: Removed requirement that Risperdal Consta is prescribed as monotherapy or as adjunctive therapy to lithium or valproate since specialist is involved in care. Added dementia-related psychosis as an indication for which coverage is not authorized per PI.		
3Q 2018 annual review: no significant changes; references reviewed and updated.	05.04.18	08.18
3Q 2019 annual review: added Perseris to policy; initial and continued therapy criteria are revised to allow approval of Risperdal Consta for members who initiate therapy during a recent inpatient visit, without the requirement to step through oral agents; added Medicaid line of business with 6/12 month approval durations; references reviewed and updated.	06.03.19	08.19
3Q 2020 annual review: no significant changes; references reviewed and updated.	05.12.20	08.20
3Q 2021 annual review: no significant changes; references reviewed and updated.	03.22.21	08.21

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2017 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.